# Study of MHB088C for Patients With Advanced Solid Malignant Tumors

Source: https://onco.cc/trials/nct07102004/  
OnCo record `nct07102004` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of QLC5508 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

Study of MHB088C for Patients With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT07102004 by Qilu Pharmaceutical Co., Ltd., with 515 participants planned, started 2023-06-20 and due to reach its primary completion in 2026-07. Interventions recorded: MHB088C for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07102004
- Phase: 1/2
- Setting: A Phase I/II Study of MHB088C for Patients With Advanced Malignant Solid Tumors
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 515

## Sources

- ClinicalTrials.gov NCT07102004: https://clinicaltrials.gov/study/NCT07102004

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [QLC5508](https://onco.cc/drugs/qlc5508/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct07102004.json